Secondary Logo

Institutional members access full text with Ovid®

Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Panahi, Yunes PhD; Kianpour, Parisa PharmD; Mohtashami, Reza MD; Jafari, Ramezan MD; Simental-Mendía, Luis E. MD; Sahebkar, Amirhossein PharmD, PhD

Journal of Cardiovascular Pharmacology: September 2016 - Volume 68 - Issue 3 - p 223–229
doi: 10.1097/FJC.0000000000000406
Original Article
Buy

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common hepatic diseases in the general adult population. Dyslipidemia, hyperuricemia, and insulin resistance are common risk factors and accompanying features of NAFLD. Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD.

Aim: To assess the effects of curcumin on metabolic profile in subjects with NAFLD.

Methods: Patients diagnosed with NAFLD (grades 1–3; according to liver sonography) were randomly assigned to curcumin (1000 mg/d in 2 divided doses) (n = 50) or control (n = 52) group for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, lipid profile, glucose, insulin, glycated hemoglobin, and uric acid concentrations were measured at baseline and after 8 weeks of follow-up.

Results: Eighty-seven subjects (n = 44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P < 0.001), low-density lipoprotein cholesterol (P < 0.001), triglycerides (P < 0.001), non–high-density lipoprotein cholesterol (P < 0.001), and uric acid (P < 0.001), whereas serum levels of high-density lipoprotein cholesterol and glucose control parameters remained unaltered. Curcumin was safe and well tolerated during this study.

Conclusion: Results of the present trial suggest that curcumin supplementation reduces serum lipids and uric acid concentrations in patients with NAFLD.

*Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;

Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran;

Medicine Quran and Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;

§Baqiyatallah University of Medical Sciences, Tehran, Iran;

Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico;

Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; and

**Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

Reprints: Amirhossein Sahebkar, PharmD, PhD, Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, PO Box: 91779-48564, Iran (e-mail: sahebkara@mums.ac.ir) or Parisa Kianpour, PharmD, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, PO Box: 19945-581, Iran (e-mail: pk.pioneer1@yahoo.com)

The authors report no conflicts of interest.

Trial registry number: IRCT2015122525641N2.

Received February 19, 2016

Accepted April 05, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.